Skip to main content
. 2022 Mar 28;12:5225. doi: 10.1038/s41598-022-09230-9

Table 3.

Multivariable logistic regression model for ECMO support in patients with ARDS.

Variable OR (95% CI) P-value
Age, year 0.95 (0.95, 0.96)  < 0.001
Sex, male (vs female) 0.98 (0.82, 1.17) 0.805
Annual Income level at ARDS treatment
Q2 (vs Q1; Lowest) 1.42 (1.09, 1.85) 0.010
Q3 (vs Q1; Lowest) 1.37 (1.07, 1.77) 0.014
Q4 (Highest) (vs Q1; Lowest) 1.35 (1.06, 1.70) 0.013
Unknown (vs Q1; Lowest) 1.12 (0.55, 2.32) 0.752
Admitting department: IM (vs non-IM) 0.40 (0.33, 0.49)  < 0.001
Hospital admission
Transfer from other hospital 1
Admission through Emergency Room 1.13 (0.73, 1.73) 0.587
Admission through outpatient clinic 1.36 (0.86, 2.14) 0.187
Annual case volume of ARDS admission
Q2: 5–14 (vs Q1 ≤ 4) 6.97 (3.84, 12.63)  < 0.001
Q3: 15–28 (vs Q1 ≤ 4) 5.24 (2.90, 9.49)  < 0.001
Q4 ≥ 28 (vs Q1 ≤ 4) 6.50 (3.60, 11.72)  < 0.001
Main diagnosis of ARDS (vs secondary diagnosis of ARDS) 1.32 (1.11, 1.58) 0.002
Sepsis associated ARDS 1.63 (1.32, 2.01)  < 0.001
Diagnosis of shock during hospitalization 1.50 (1.16, 1.93) 0.002
CCI at hospital admission for ARDS
2–3 (n = 2,722) vs 0–1 (n = 1,463) 1.43 (1.08, 1.88) 0.011
4–5 (n = 2,526) vs 0–1 (n = 1,463) 1.20 (0.89, 1.60) 0.227
6–7 (n = 1,767) vs 0–1 (n = 1,463) 1.07 (0.77, 1.49) 0.675
 ≥ 8 (n = 1,697) vs 0–1 (n = 1,463) 0.89 (0.63, 1.25) 0.504
NMBA use 7.39 (5.83, 9.37)  < 0.001
Duration of CRRT use, day 1.13 (1.09, 1.16)  < 0.001
Duration of Mechanical Ventilator use, day 1.03 (1.02, 1.04)  < 0.001
Experience of CPR during hospitalization 1.70 (1.36, 2.13)  < 0.001
Year of admission for ARDS
2015 (vs 2014) 1.13 (0.81, 1.58) 0.464
2016 (vs 2014) 1.05 (0.76, 1.44) 0.770
2017 (vs 2014) 1.12 (0.81, 1.56) 0.483
2018 (vs 2014) 1.30 (0.94, 1.78) 0.110
2019 (vs 2014) 1.57 (1.14, 2.15) 0.005

Hosmer Lemeshow test: Chi-square, 3.66, df = 8, P = 0.886.

ARDS acute respiratory distress syndrome, ECMO extracorporeal membrane oxygenation, OR odds ratio, CI confidence interval, IM internal medicine, USD United States Dollars, NMB neuromusclar blockade, CRRT continuous renal replacement therapy, CPR cardiopulmonary resuscitation.